Novartis invests in early technical improvement capabilities for next-generation biotherapeutics

  • Multi-year funding of USD 300m will create built-in scientific atmosphere to ship on growing progress and variety of biotherapeutics portfolio  
  • Enhanced capability and processes anticipated to result in sooner transition instances from pre-clinical to first-in-human research
  • Dedication to early section biologics improvement in Switzerland, Slovenia & Austria

Basel, Sept 12, 2022 — Novartis right this moment introduced it’s investing in next-generation biotherapeutics with the creation of a completely built-in, devoted USD 300m scientific atmosphere that can bolster its capability and capabilities for early technical improvement of biologics. Spanning each drug substance and drug product improvement, the multi-year funding will likely be applied throughout current Novartis places in Switzerland, Slovenia and Austria, strengthening Novartis capacity to ship on the growing progress and variety of its early-stage biotherapeutics portfolio.

“Throughout the trade, biotherapeutics account for nearly one-half of all latest new drug approvals and have monumental potential to deal with unmet want throughout a variety of illnesses,” mentioned Reto Fischer, Head of Technical Analysis Division, International Drug Improvement (GDD), Novartis. “We’re constructing the scientific atmosphere essential to convey these complicated biologic compounds from the bench by way of improvement in an built-in, seamless, and speedy vogue. In doing so, we’re supporting our broader ambition to allow sooner improvement and centered prioritization throughout our world portfolio.”

The Novartis early-stage biologics portfolio has grown considerably within the final 15 years. It has additionally expanded past standard monoclonal antibodies into a variety of novel improvement candidates with potential to be first-in-class, best-in-class, or each, together with antibody-drug conjugates and therapeutic proteins.

This funding is meant to place Novartis on the forefront of biotherapeutic improvement, by supporting the corporate’s more and more subtle pipeline with essentially the most superior technical infrastructure, alongside the best stage of capabilities. It should create seamless, end-to-end improvement and manufacturing environments by embedding biologics improvement inside current Novartis industrial manufacturing amenities in Slovenia and Austria in addition to by establishing a biologic’s hub on the Basel St. Johann Campus in Switzerland alongside the NIBR biologics heart fostering scientific innovation, know-how management and expertise attraction. Collectively these commitments will improve improvement processes focusing on sooner transition instances from pre-clinical to first in human research.

Particularly, the funding will:

  • Strengthen the Novartis St. Johann campus in Basel by investing USD 100M to ascertain a biologics hub to enrich the present NIBR Biologics Middle; 
  • Create a biocampus in Mengeš, Slovenia with an funding of USD 110M in scientific manufacturing capabilities (non cGMP and cGMP) and technical improvement capabilities in proximity of improvement operations; and
  • Amplify synergies and strategic proximity on the Schaftenau campus in Austria with a USD 60M USD funding in improvement manufacturing capability and capabilities.

“The science of creating biologics is more and more subtle, and we’re excited to satisfy its challenges head-on,” mentioned Jonathan Novak, International Head for Biologics, Technical Analysis Division, GDD at Novartis. “We stay up for amplifying the information and expertise of our associates to make sure that biologics improvement is an exhilarating and rewarding course of for our present and future colleagues – and that’s finally a supply of profoundly revolutionary new therapies for sufferers worldwide.”

This media replace accommodates forward-looking statements throughout the that means of the US Personal Securities Litigation Reform Act of 1995. Ahead-looking statements can typically be recognized by phrases equivalent to “potential,” “can,” “will,” “plan,” “might,” “might,” “would,” “anticipate,” “anticipate,” “look ahead,” “imagine,” “dedicated,” “investigational,” “pipeline,” “launch,” or related phrases, or by specific or implied discussions relating to potential advertising and marketing approvals, new indications or labeling for the investigational or authorised merchandise described on this media replace, or relating to potential future revenues from such merchandise. You shouldn’t place undue reliance on these statements. Such forward-looking statements are primarily based on our present beliefs and expectations relating to future occasions, and are topic to important recognized and unknown dangers and uncertainties. Ought to a number of of those dangers or uncertainties materialize, or ought to underlying assumptions show incorrect, precise outcomes might differ materially from these set forth within the forward-looking statements. There might be no assure that the investigational or authorised merchandise described on this media replace will likely be submitted or authorised on the market or for any extra indications or labeling in any market, or at any explicit time. Nor can there be any assure that such merchandise will likely be commercially profitable sooner or later. Specifically, our expectations relating to such merchandise may very well be affected by, amongst different issues, the uncertainties inherent in analysis and improvement, together with scientific trial outcomes and extra evaluation of current scientific information; regulatory actions or delays or authorities regulation typically; world traits towards well being care value containment, together with authorities, payor and common public pricing and reimbursement pressures and necessities for elevated pricing transparency; our capacity to acquire or keep proprietary mental property safety; the actual prescribing preferences of physicians and sufferers; common political, financial and enterprise situations, together with the consequences of and efforts to mitigate pandemic illnesses equivalent to COVID-19; security, high quality, information integrity or manufacturing points; potential or precise information safety and information privateness breaches, or disruptions of our info know-how methods, and different dangers and components referred to in Novartis AG’s present Type 20-F on file with the US Securities and Trade Fee. Novartis is offering the knowledge on this media replace as of this date and doesn’t undertake any obligation to replace any forward-looking statements contained on this media replace on account of new info, future occasions or in any other case.

About Novartis
Novartis is reimagining medication to enhance and prolong individuals’s lives. As a number one world medicines firm, we use revolutionary science and digital applied sciences to create transformative remedies in areas of nice medical want. In our quest to search out new medicines, we constantly rank among the many world’s prime corporations investing in analysis and improvement. Novartis merchandise attain practically 800 million individuals globally and we’re discovering revolutionary methods to develop entry to our newest remedies. About 108,000 individuals of greater than 140 nationalities work at Novartis world wide. Discover out extra at

Novartis is on Twitter. Signal as much as comply with @Novartis at 
For Novartis multimedia content material, please go to 
For questions concerning the web site or required registration, please contact [email protected] 

# # #

Novartis Media Relations
E-mail: [email protected] 

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected] 

Central   North America  
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440
Nicole Zinsli-Somm +41 61 324 3809 Alina Levchuk +1 862 778 3372
Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

Supply hyperlink